fezf1 Antibody

What is FEZF1 and why is it important in research?

FEZF1 functions as a transcription factor critical for nervous system development but has increasingly been recognized for its role in cancer progression. Research has demonstrated that FEZF1 can bind to multiple key genes in the Wnt signaling pathway, a critical pathway in oncogenesis. Studies have shown significant associations between FEZF1 expression and clinical outcomes in several cancer types, particularly cervical cancer where it prominently associates with recurrence-free survival (p=0.015) . The protein serves as both a potential biomarker and therapeutic target, making antibodies against it valuable tools for understanding cancer biology and developing new treatments.

What types of FEZF1 antibodies are available for research applications?

FEZF1 antibodies are available targeting different epitope regions of the protein, each with specific applications and reactivity profiles. Common variants include antibodies targeting the C-terminal region, N-terminal regions (such as AA 67-96), and mid-protein regions (such as AA 199-280). Most commercial antibodies are rabbit polyclonal antibodies, though they vary in their specific applications and species reactivity . Researchers should select antibodies based on their experimental design requirements, including:

• Application needs (Western blot, IHC, IF, ELISA)

• Target species (human, mouse, rat, etc.)

• Epitope requirements

• Conjugation needs (unconjugated, HRP, FITC, biotin)

The antibody's specific binding region can significantly impact experimental outcomes, particularly when studying protein-protein interactions or domain-specific functions.

What applications are FEZF1 antibodies commonly used for?

FEZF1 antibodies have demonstrated utility across multiple applications critical to cancer and developmental biology research. Common applications include:

• ELISA for protein quantification

• Immunofluorescence with both cultured cells (IF-cc) and paraffin-embedded sections (IF-p)

• Immunohistochemistry with frozen sections (IHC-fro) and paraffin-embedded sections (IHC-p)

• Immunocytochemistry (ICC)

• Western blotting for protein expression analysis

When selecting an antibody for a specific application, researchers should verify the antibody has been validated for that particular use. For instance, antibodies targeting amino acids 199-280 have demonstrated effectiveness across multiple applications including ELISA, IF, IHC, and ICC with human samples .

How should I validate a new FEZF1 antibody before experimental use?

Proper validation of FEZF1 antibodies is essential before incorporating them into critical experiments. A comprehensive validation approach should include:

• Positive and negative control samples (tissues or cell lines with known FEZF1 expression levels)

• Western blot analysis to confirm expected molecular weight (~51-55 kDa)

• Testing antibody specificity using FEZF1 knockdown samples via siRNA or shRNA (as described in cervical cancer studies)

• Comparison of staining patterns with published literature

• Cross-validation with different antibody clones or antibodies targeting different epitopes

For advanced validation, consider using ChIP-seq to confirm binding specificity, particularly important when studying FEZF1's role as a transcription factor binding to Wnt pathway genes .

How can I effectively use FEZF1 antibodies to study its role in cancer pathways?

To effectively investigate FEZF1's role in cancer pathways, particularly the Wnt signaling pathway, researchers should employ multiple complementary approaches:

• Chromatin immunoprecipitation (ChIP) assays to identify FEZF1 binding sites in cancer cell genomes. Recent research has successfully used this approach to reveal that FEZF1 can bind to multiple key genes in the Wnt signaling pathway in HeLa cells .

• Combine FEZF1 antibody staining with markers of Wnt pathway activation (such as β-catenin) to determine correlation between FEZF1 expression and pathway activity in tissue samples.

• Use FEZF1 antibodies in protein-protein interaction studies (co-IP) to identify binding partners that may contribute to its role in cancer progression.

• Perform sequential immunohistochemistry to co-localize FEZF1 with other cancer biomarkers to establish association patterns.

Research has shown that FEZF1 may act as a transcriptional activator of the Wnt signaling pathway in cervical cancer, providing valuable insights into potential therapeutic targets .

What is the relationship between FEZF1 and FEZF1-AS1, and how can I study both?

FEZF1-AS1 is a long non-coding RNA (lncRNA) that is upregulated in lung adenocarcinoma and is mediated by FEZF1 . To effectively study the relationship between FEZF1 protein and FEZF1-AS1:

• Use RNA-protein interaction assays in conjunction with FEZF1 antibodies to determine if there is direct binding between FEZF1 protein and FEZF1-AS1.

• Perform subcellular fractionation followed by immunoblotting with FEZF1 antibodies and RT-qPCR for FEZF1-AS1 to determine their respective cellular localizations. Research has shown conflicting reports about FEZF1-AS1 localization, with some studies showing it predominantly in the cytoplasm and others finding it in both cytoplasm and nucleus .

• Conduct knockdown or overexpression studies of one molecule (FEZF1 or FEZF1-AS1) and observe effects on the other's expression using antibodies for protein detection and qPCR for RNA.

• Use chromatin isolation by RNA purification (ChIRP) with FEZF1 antibodies to investigate if FEZF1-AS1 and FEZF1 co-localize on chromatin.

Understanding this relationship is critical as both molecules have been implicated in cancer progression through potentially overlapping mechanisms .

How can I quantify FEZF1 protein expression levels accurately in experimental samples?

For accurate quantification of FEZF1 protein expression, researchers should consider these methodological approaches:

• Western blot with densitometry analysis normalized to appropriate loading controls (β-actin, GAPDH, etc.)

• ELISA-based quantification with properly validated FEZF1 antibodies

• Advanced protein quantitation systems like the Octet N1 system, which can deliver rapid, direct quantitation of proteins in seconds. This system has shown comparable results to HPLC methods for antibody quantification and could be applied to FEZF1 studies .

• Establish a standard curve using recombinant FEZF1 protein at known concentrations

A comparison of methodologies is presented in the table below, based on similar protein quantification approaches:

When analyzing clinical samples, statistical analysis should employ methods like two-tailed Student t-test or one-way ANOVA, with p<0.05 considered statistically significant .

What controls are essential when studying FEZF1 expression in cancer tissues?

When studying FEZF1 expression in cancer tissues, several controls are essential for experimental validity:

• Matched normal adjacent tissue from the same patient to establish baseline expression levels. Research has shown significant upregulation of FEZF1 in NSCLC samples compared to corresponding normal tissues .

• Positive control tissues known to express FEZF1 (based on research showing high expression in CESC, COADREAD, ESCA, LUNG, and STAD cancer types) .

• Negative control tissues with minimal FEZF1 expression (research suggests BRCA, LIHC, and PRAD may have lower expression in some samples) .

• Isotype control antibodies to assess non-specific binding

• Antibody absorption controls where the antibody is pre-incubated with recombinant FEZF1 protein before application to tissue

• FEZF1 knockdown or knockout cell lines as negative controls for antibody specificity

What are the optimal conditions for using FEZF1 antibodies in immunohistochemistry?

For optimal immunohistochemistry (IHC) with FEZF1 antibodies, consider the following protocol recommendations:

• Fixation and Embedding:

  • 10% neutral buffered formalin fixation for 24-48 hours

  • Paraffin embedding with standard protocols

• Antigen Retrieval:

  • Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) for 20 minutes

  • Allow slides to cool to room temperature for 20 minutes

• Blocking and Antibody Incubation:

  • Block with 5% normal serum from the same species as the secondary antibody

  • Incubate with primary FEZF1 antibody (typically at 1:100-1:500 dilution) overnight at 4°C

  • Wash thoroughly with PBS or TBS

  • Incubate with appropriate secondary antibody (1:200-1:1000) for 1 hour at room temperature

• Detection and Counterstaining:

  • Develop with DAB or other appropriate chromogen

  • Counterstain with hematoxylin

  • Dehydrate, clear, and mount

For immunofluorescence applications, protocols should be adjusted to use fluorophore-conjugated secondary antibodies and appropriate mounting media with DAPI for nuclear counterstaining .

How should I troubleshoot weak or non-specific signals with FEZF1 antibodies?

When encountering weak or non-specific signals with FEZF1 antibodies, systematically address these common issues:

• For weak signals:

  • Increase antibody concentration (try a titration series)

  • Extend primary antibody incubation time or temperature

  • Enhance antigen retrieval conditions (longer times or higher temperatures)

  • Use signal amplification systems like tyramide signal amplification (TSA)

  • Ensure sample is properly fixed and processed to preserve epitopes

• For non-specific signals:

  • Optimize blocking conditions (increase blocking reagent concentration or time)

  • Reduce primary antibody concentration

  • Include additional washing steps

  • Pre-absorb antibody with non-specific proteins

  • Use more specific detection systems

  • Validate with positive and negative controls

  • Consider using antibodies targeting different epitopes of FEZF1

Additionally, when studying FEZF1 in cancer samples, consider the potential cross-reactivity with FEZF1-AS1, which has been shown to be upregulated in several cancer types and could affect interpretation of results .

What are the best methods for FEZF1 knockdown validation when testing antibody specificity?

To validate FEZF1 knockdown for antibody specificity testing, consider these methodological approaches:

• siRNA/shRNA Knockdown:

  • Use at least two different siRNA or shRNA sequences targeting different regions of FEZF1 mRNA

  • For shRNA lentiviruses, co-transfect HEK293T cells with pLKO.1 shRNA vectors and packaging plasmids (psPAX2 and pMD2.G)

  • Transduce target cells (e.g., C33A and SiHa cells as demonstrated in literature) with shRNA lentiviruses

  • Select transduced cells with puromycin (1 μg/ml) for 3 days

  • After selection, grow cell pools in media without puromycin for 24 hours before analysis

• CRISPR/Cas9 Knockout:

  • Design guide RNAs targeting early exons of FEZF1

  • Confirm knockout by sequencing and Western blot

• Validation Methods:

  • RT-qPCR to confirm mRNA reduction

  • Western blot with FEZF1 antibody to confirm protein reduction

  • Functional assays (proliferation, migration) to confirm biological effect of knockdown

  • Immunocytochemistry to visualize reduction in staining intensity

These protocols have been successfully implemented in research showing that FEZF1 knockdown significantly decreased cell proliferation, growth, and migration in cancer cell lines .

How do I optimize Western blotting protocols for FEZF1 detection?

For optimal Western blot detection of FEZF1, follow these protocol recommendations:

• Sample Preparation:

  • Lyse cells in RIPA buffer supplemented with protease inhibitors

  • Include phosphatase inhibitors if studying phosphorylation status

  • Sonicate briefly to shear DNA and reduce viscosity

  • Centrifuge at 14,000 × g for 15 minutes at 4°C to remove debris

• Gel Electrophoresis:

  • Load 20-50 μg of total protein per lane

  • Use 10% SDS-PAGE gels for optimal separation around the expected FEZF1 molecular weight (51-55 kDa)

• Transfer and Blocking:

  • Transfer proteins to PVDF membrane (better for subsequent stripping/reprobing)

  • Block with 5% non-fat dry milk in TBST for 1 hour at room temperature

• Antibody Incubation:

  • Incubate with primary FEZF1 antibody at manufacturer's recommended dilution (typically 1:500-1:2000) overnight at 4°C

  • Wash 3-5 times with TBST

  • Incubate with HRP-conjugated secondary antibody (1:5000-1:10000) for 1 hour at room temperature

  • Wash thoroughly 5-6 times with TBST

• Detection and Analysis:

  • Develop using ECL substrate

  • For quantification, normalize FEZF1 signal to loading controls (β-actin, GAPDH)

  • Consider using fluorescent secondary antibodies for more accurate quantification

For challenging samples, consider enrichment techniques like immunoprecipitation before Western blotting to increase sensitivity for low-abundance FEZF1 protein .

How can I optimize ChIP protocols for studying FEZF1 binding to target genes?

For effective ChIP analysis of FEZF1 binding to target genes, particularly in the Wnt signaling pathway, follow these optimization steps:

• Crosslinking:

  • Fix cells with 1% formaldehyde for 10 minutes at room temperature

  • Quench with 125 mM glycine for 5 minutes

  • Wash cells with cold PBS containing protease inhibitors

• Chromatin Preparation:

  • Lyse cells in appropriate buffers

  • Sonicate to generate DNA fragments of 200-500 bp

  • Confirm fragment size by agarose gel electrophoresis

• Immunoprecipitation:

  • Pre-clear chromatin with protein A/G beads

  • Incubate cleared chromatin with FEZF1 antibody (3-5 μg) overnight at 4°C

  • Include IgG control immunoprecipitation

  • Add protein A/G beads and incubate for 2-4 hours

  • Wash extensively with increasingly stringent wash buffers

• DNA Recovery and Analysis:

  • Reverse crosslinks by heating at 65°C overnight

  • Treat with RNase A and Proteinase K

  • Purify DNA using column-based methods

  • Analyze enrichment by qPCR targeting Wnt pathway genes

This approach has been successfully employed to demonstrate that FEZF1 can bind to multiple key genes in the Wnt signaling pathway in HeLa cells, providing insight into its role as a transcriptional activator .

What are the key Wnt pathway genes that FEZF1 has been shown to bind to?

Research using ChIP assays has revealed that FEZF1 binds to multiple key genes in the Wnt signaling pathway. While analyzing these binding interactions:

• Focus on canonical Wnt pathway components including:

  • β-catenin (CTNNB1) - the core component of the Wnt pathway

  • TCF/LEF family transcription factors

  • Frizzled (FZD) receptors

  • LRP5/6 co-receptors

  • Downstream effector genes like CCND1 (Cyclin D1), MYC, and AXIN2

• Design ChIP-qPCR primers for promoter regions of these genes

• Validate binding using reporter assays with wild-type and mutated binding sites

• Correlate FEZF1 binding with expression changes of these genes following FEZF1 knockdown or overexpression

Analysis should include assessment of β-catenin protein levels and localization, as research has shown that FEZF1 can activate the Wnt pathway in cancer cells . This approach helps establish the mechanistic link between FEZF1 expression and cancer progression through Wnt signaling modulation.

How can FEZF1 antibodies be used for patient stratification in cancer prognosis?

FEZF1 antibodies can be valuable tools for patient stratification in cancer prognosis through several methodological approaches:

• Immunohistochemistry (IHC) Scoring:

  • Develop a standardized scoring system based on staining intensity and percentage of positive cells

  • Classify patients into high and low FEZF1 expression groups (as demonstrated in studies where patients were divided into high and low expression groups based on median expression)

  • Correlate expression levels with clinical outcomes using Kaplan-Meier survival analysis

• Tissue Microarray Analysis:

  • Use FEZF1 antibodies on tissue microarrays to efficiently screen large cohorts

  • Combine with other biomarkers for multi-parameter stratification

• Liquid Biopsy Applications:

  • Develop protocols to detect FEZF1 in circulating tumor cells using antibody-based enrichment

  • Correlate with disease progression and treatment response

What are the differences in FEZF1 expression across different cancer types?

FEZF1 shows variable expression patterns across different cancer types, which has important implications for its use as a biomarker:

This expression pattern data helps researchers select appropriate cancer types for FEZF1-focused studies and informs the potential utility of FEZF1 as a biomarker in specific cancer contexts.

What emerging applications of FEZF1 antibodies should researchers be aware of?

As FEZF1 research continues to evolve, several emerging applications of FEZF1 antibodies are becoming increasingly important:

• Therapeutic Development:

  • Utilizing FEZF1 antibodies to develop antibody-drug conjugates targeting FEZF1-expressing cancer cells

  • Screening for antibodies that can functionally inhibit FEZF1's transcriptional activity

• Single-Cell Analysis:

  • Incorporating FEZF1 antibodies into CyTOF and single-cell proteomics workflows

  • Combining with RNA-seq for multi-omic profiling of FEZF1 activity at single-cell resolution

• Relationship with Non-coding RNAs:

  • Investigating the interaction between FEZF1 protein and FEZF1-AS1 lncRNA, which has been implicated in cancer progression

  • Developing methods to simultaneously detect FEZF1 protein and FEZF1-AS1 RNA in the same samples

• Liquid Biopsy Development:

  • Creating sensitive detection methods for FEZF1 in circulating tumor cells

  • Exploring FEZF1 as a blood-based biomarker for early cancer detection

• Pathway Interaction Mapping:

  • Using proximity ligation assays with FEZF1 antibodies to map protein-protein interactions in situ

  • Further characterizing FEZF1's role in Wnt pathway regulation through advanced imaging techniques